other_material
confidence high
sentiment positive
materiality 0.55
Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated
Marker Therapeutics, Inc.
- First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.
- No treatment-related adverse events observed in first patient; safety consistent with prior MAR-T cell data.
- OTS product aims to accelerate time to treatment to as fast as 72 hours using healthy donor material.
- Non-dilutive funding from FDA, NIH SBIR, and CPRIT supports OTS program without affecting cash runway.
- APOLLO study in lymphoma reported 66% objective response rate and durable complete responses.